A Phase 1 Study of HMPL-306 in Advanced Hematological Malignancies with Isocitrate Dehydrogenase (IDH) Mutations
This is an early-stage research study, called a Phase 1 trial, looking into a new medication named HMPL-306. It's for adults (18 years and older) who have advanced blood cancers, such as acute myeloid leukemia, certain types of myelodysplastic syndrome, or angio-immunoblastic T-cell lymphoma. Crucially, the cancer cells in these patients must have a specific genetic change (mutation) known as an and (an "IDH mutation"). The main goal of this first phase is to see how safe the new drug is, what side effects it might cause, and how the body handles it. This kind of study helps scientists understand if a new medicine is promising enough to be tested in more people later on.
At a glance
What is this study about?
This research study is about a new drug called HMPL-306. It's designed for adults who have certain blood cancers, like acute myeloid leukemia (AML), myelodysplastic syndrome/myeloproliferative neoplasm (MDS/MPN), or angio-immunoblastic T-cell lymphoma. What really matters for this study is that the cancer cells must have a specific genetic change, which doctors call an IDH mutation. This 'IDH mutation' makes the cancer different and might respond to drugs that target it.
This is a Phase 1 study, which means it's one of the first times this new drug is being tested in people. The main purpose at this stage is to find out if HMPL-306 is safe, what dose can be given, and if there are any side effects. Researchers will also learn how the body uses and gets rid of the drug. It's not primarily about seeing if the drug cures the cancer, but rather about gathering important safety information and understanding how it works.
Finding new ways to treat blood cancers, especially those with specific genetic changes, is a big step in improving care. If this early study shows that HMPL-306 is safe and works in the way researchers expect, it could then move on to larger studies to see if it can help patients with these conditions more effectively.
Key takeaways
- This is an early-stage study for a new drug called HMPL-306.
- It's for adults with certain advanced blood cancers with a specific 'IDH mutation'.
- The main goal is to check the drug's safety and how it works in the body.
- Participation involves regular clinic visits and close monitoring.
- There are potential benefits and unconfirmed risks; you can leave the study at any time.
Who may be eligible?
This study is looking for adults aged 18 or older. It is open to both men and women.
To join, you must have an advanced blood cancer. This includes acute myeloid leukemia (AML), certain types of myelodysplastic syndrome/myeloproliferative neoplasm (MDS/MPN), or a specific type of lymphoma called angio-immunoblastic T-cell lymphoma. Your doctors will need to confirm the exact type of your cancer.
Crucially, your cancer cells must have a specific genetic change, known as an 'IDH mutation.' Your medical team will perform tests to check for this mutation to see if you might be eligible for the study.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- Are you 18 years old or older?
- Have you been diagnosed with an advanced blood cancer like acute myeloid leukemia (AML) or certain types of myelodysplastic syndrome/myeloproliferative neoplasm (MDS/MPN), or angio-immunoblastic T-cell lymphoma?
- Have your doctors confirmed that your cancer has an 'IDH mutation'?
- Are you able to attend regular clinic visits for check-ups and tests?
- Are you able to give your informed consent to participate?
What does participation involve?
Taking part in this study means you would receive the new drug, HMPL-306, following a specific schedule determined by the researchers. You would have regular visits to the clinic for medical check-ups, blood tests, and other assessments to monitor your health and how your body reacts to the drug. These visits help the study team understand the drug's effects and any changes in your condition.
The study involves carefully tracking any side effects you might experience. You would be fully informed about what each visit involves and the total length of your participation, which would depend on how your body responds to the treatment and the study's design. There will also be follow-up appointments after you stop taking the study drug to ensure your well-being.
Potential risks and benefits
Locations (1)
- —UnverifiedSpain
Common questions
What is an 'IDH mutation'?
It's a specific genetic change found in the cells of some cancers, which the new drug aims to target.
Is this drug approved for use yet?
No, HMPL-306 is a new drug and is still in the early stages of research and not yet approved.
Will I definitely get better if I join this study?
This early study focuses on safety, so there's no guarantee the drug will improve your cancer; it's a possibility, not a certainty.
What happens after the study ends?
Your medical team will discuss the best ongoing care for you based on your health and findings from the study.
Who pays for the treatment in the study?
Typically, the study sponsor covers the cost of the study drug and related tests during your participation.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.